Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498309 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1HMOX1SLC6A2SLC6A4 | |
| SCHEMBL11578 | 0.93 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2A6 | |
| SCHEMBL4989494 | 0.93 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2A6 | |
| SCHEMBL2131604 | 0.93 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2A6 | |
| SCHEMBL28275254 | 0.80 | CYP3A4 (0.49) | ALDH1A1MAPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11602636 | 0.78 | CYP2A6 (0.50) | ALDH1A1MAPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4503863 | 0.75 | SYK (0.39) | SYK | |
| SCHEMBL5013583 | 0.75 | SYK (0.39) | SYK | |
| SCHEMBL28550933 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28263800 | 0.74 | CYP2A6 (0.44) | MAPK1SLC6A2SLC6A4SLC6A3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893562-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | Merck Frosst Canada Ltd. (CA) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133559-A1 | REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B | MERCK FROSST CANADA LTD. (CA) | 2006-12-21 | — | — | WO | claimed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2020025748-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | INTERVET INTERNATIONAL B.V. (NL) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300863-A1 | PROCESS TO MAKE A SELECTIVE CATHEPSIN CYSTEINE PROTEASE INHIBITOR | CTSB, CTSF, CTSZ | ALDH1A1 2183/4885MAPK1 2644/4885HMOX1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.